Apricus Biosciences has sold its specialty CRO subsidiary, Bio-Quant, Inc., to BioTox Sciences, a San Diego-based CRO. Apricus will receive a minimum of $5 million in upfront and future payments of as much as $20 million during the next 10 years. Apricus has also retained all NexMed-related research conducted by Bio-Quant and Bio-Quant’s diagnostic kit business. “While our Bio-Quant subsidiary has been driving revenues over the past year, this divesture represents a key strategic decision for A...